Amneal to Participate at the 2023 Wells Fargo Healthcare Conference

Rhea-AI Summary

Amneal Pharmaceuticals to participate at the 2023 Wells Fargo Healthcare Conference on September 7, 2023

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Chief Financial Officer, will participate at the 2023 Wells Fargo Healthcare Conference on September 7, 2023 in Boston. Mr. Patel will also be hosting a fireside chat at 8:00 AM Eastern Time and a live webcast will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.com. A replay of the webcast will be posted shortly after the presentation and will be available for 90 days following the event.

About Amneal
Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is a fully integrated global pharmaceuticals company. We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of approximately 270 pharmaceutical products, primarily within the United States. In its Generics segment, the Company is expanding across a broad range of complex product categories and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders, with a pipeline focused on unmet needs. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more information, please visit www.amneal.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230825020989/en/

Anthony DiMeo

Head of Investor Relations

Anthony.DiMeo@amneal.com

Source: Amneal Pharmaceuticals, Inc.